BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Manual for Conservative SUVs For Seniors - 2Well known SUVs With Low Energy Utilization In 2024
- 3Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- 4Greece eyes migrant repatriation centres outside the EU
- 5Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- 4 astronauts are en route home from ISS after medical issue forces early exit
- The Best Cell phone Brands for Tech Aficionados
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Instructions to Boost Your True capacity with a Brain research Degree
- A whale stranded at a Baltic Sea resort has swum off a sandbank. But it isn't safe yet
- IDF Home Front Command extends siren warning times for Hezbollah rockets in North
- Regeneron's experimental therapy combo effective in untreated cancer patients
- 10 Asian Countries Perfect for Solo Female Travelers
